

Supplemental references

- E1. Said Y, Filippatou A, Tran C, et al. Real-world clinical experience with serum MOG and AQP4 antibody testing by live versus fixed cell-based assay. *Ann Clin Transl Neurol* 2025;12:556-564.
- E2. Yang J, Kim SM, Kim YJ, et al. Accuracy of the Fluorescence-Activated Cell Sorting Assay for the Aquaporin-4 Antibody (AQP4-Ab): Comparison with the Commercial AQP4-Ab Assay Kit. *PLoS One* 2016;11:e0162900.
- E3. Prain K, Woodhall M, Vincent A, et al. AQP4 Antibody Assay Sensitivity Comparison in the Era of the 2015 Diagnostic Criteria for NMOSD. *Front Neurol* 2019;10:1028.
- E4. Hoftberger R, Sabater L, Marignier R, et al. An optimized immunohistochemistry technique improves NMO-IgG detection: study comparison with cell-based assays. *PLoS One* 2013;8:e79083.
- E5. Waters P, Reindl M, Saiz A, et al. Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica. *J Neurol Neurosurg Psychiatry* 2016;87:1005-1015.
- E6. Vij R, Jonokuchi AJ, Kister I. Letter on "Real-World Clinical Experience With Serum MOG and AQP4 Antibody Testing by Live Versus Fixed Cell-Based Assay". *Ann Clin Transl Neurol* 2025.
- E7. Tzartos JS, Karagiorgou K, Tzanetakos D, et al. Deciphering anti-MOG IgG antibodies: Clinical and radiological spectrum, and comparison of antibody detection assays. *J Neurol Sci* 2020;410:116673.
- E8. Reindl M, Schanda K, Woodhall M, et al. International multicenter examination of MOG antibody assays. *Neurol Neuroimmunol Neuroinflamm* 2020;7.
- E9. Gastaldi M, Scaranzin S, Jarius S, et al. Cell-based assays for the detection of MOG antibodies: a comparative study. *J Neurol* 2020;267:3555-3564.
- E10. Cross H, Sabiq F, Ackermans N, et al. Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Positive Patients in a Multi-Ethnic Canadian Cohort. *Front Neurol* 2020;11:525933.
- E11. Tea F, Lopez JA, Ramanathan S, et al. Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination. *Acta Neuropathol Commun* 2019;7:145.
- E12. Seok JM, Waters P, Jeon MY, et al. Clinical Usefulness of a Cell-based Assay for Detecting Myelin Oligodendrocyte Glycoprotein Antibodies in Central Nervous System Inflammatory Disorders. *Ann Lab Med* 2024;44:56-63.
- E13. Waters PJ, Komorowski L, Woodhall M, et al. A multicenter comparison of MOG-IgG cell-based assays. *Neurology* 2019;92:e1250-e1255.

E14. Banwell B, Bennett JL, Marignier R, et al. Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria. *Lancet Neurol* 2023;22:268-282.

E15 Uzawa A, Oertel FC, Mori M, Paul F, Kuwabara S. NMOSD and MOGAD: an evolving disease spectrum. *Nat Rev Neurol* 2024;20:602–619.

E16 Lipps P, Ayroza Galvão Ribeiro Gomes AB, Kulsvehagen L, et al. Ongoing Challenges in the Diagnosis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. *JAMA Neurol* 2023;80:1377–1379.

E17 Dalmau J, Graus F. Antibody-Mediated Encephalitis. *N Engl J Med* 2018;378:840–851.

E18 Hench J, Hultschig C, Bratic Hench I, et al. Rapid brain lymphoma diagnostics through nanopore sequencing of cytology-negative cerebrospinal fluid. *Acta Neuropathol* 2024;148:36.

E19 Fourgeaud J, Regnault B, Ok V, et al. Performance of clinical metagenomics in France: a prospective observational study. *Lancet Microbe* 2024;5:e52–e61.

E20 Teunissen CE, Petzold A, Bennett JL, et al. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. *Neurology* 2009;73:1914–1922.

E21 Yalachkov Y, Schäfer JH, Jakob J, et al. Effect of estimated blood volume and body mass index on GFAP and nfl levels in the serum and CSF of patients with multiple sclerosis. *Neurol Neuroimmunol Neuroinflamm* 2023;10.

E22 Benkert P, Meier S, Schaedelin S, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. *Lancet Neurol*. 2022;21:246–257.

E23 Hyun J-W, Kim Y, Kim KH, et al. CSF GFAP levels in double seronegative neuromyelitis optica spectrum disorder: no evidence of astrocyte damage. *J Neuroinflammation* 2022;19:86.

E24. Meier S, Willemse EAJ, Schaedelin S, et al. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. *JAMA Neurol* 2023;80:287-297.

E25. Segal Y, Mangioris G, Lennon V, et al. CSF cytokine, chemokine and injury biomarker profile of glial fibrillary acidic protein (GFAP) autoimmunity. *Ann Clin Transl Neurol* 2025;12:855-860.

- E26. Ringelstein M, Ayzenberg I, Lindenblatt G, et al; Neuromyelitis Optica Study Group (NEMOS). Interleukin-6 Receptor Blockade in Treatment-Refractory MOG-IgG-Associated Disease and Neuromyelitis Optica Spectrum Disorders. *Neurol Neuroimmunol Neuroinflamm* 2021;9:e1100.
- E27. Kaneko K, Sato DK, Nakashima I, et al. CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications. *J Neurol Neurosurg Psychiatry* 2018;89:927-936.
- E28. Hyun J-W, Kim S, Moon J, et al. HLA Association With AQP4-IgG-Positive Neuromyelitis Optica Spectrum Disorder in the Korean Population. *Neurol Neuroimmunol Neuroinflamm* 2025;12:e200366.
- E29. Bruijstens AL, Wong YYM, van Pelt DE, et al. HLA association in MOG-IgG- and AQP4-IgG-related disorders of the CNS in the Dutch population. *Neurol Neuroimmunol Neuroinflamm* 2020; 7:e702.
- E30. Grant-Peters M, Passos GRD, Yeung H-Y, et al. No strong HLA association with MOG antibody disease in the UK population. *Ann Clin Transl Neurol* 2021;8:1502–1507.
- E31. Sun X, Qiu W, Wang J, et al. Myelin oligodendrocyte glycoprotein-associated disorders are associated with HLA subtypes in a Chinese paediatric-onset cohort. *J Neurol Neurosurg Psychiatry* 2020;91:733–739.
- E32. Vorasoot N, Abdulrahman YJ, Mateen F, et al. Dried blood spot improves global access to aquaporin-4-IgG testing for neuromyelitis optica. *Ann Clin Transl Neurol* 2024;11:2855–2865.
- E33. Tsaktanis T, Ammon L, Löblein L, et al. Serum levels of aryl hydrocarbon receptor plasma agonist activity are reduced in patients with NMOSD and correlate with disease activity. *Neurol Neuroimmunol Neuroinflamm* 2025;12:e200457.